Collaborative Testing Services, Inc
FORENSIC TESTING PROGRAM

P.O. Box 650820
Sterling, VA 20165-0820
e-mail: forensics@cts-interlab.com
Telephone: +1-571-434-1925
Web site: www.cts-forensics.com

Manufacturer's Information
Test No. 19-589: DNA Interpretation

Each sample pack contained digital files consisting of electropherograms from DNA profiles of two known samples (Items 1 & 2) and two questioned samples (Items 3 & 4). Participants were requested to evaluate the electropherograms and interpret the data using their existing protocols.

SAMPLE PREPARATION: Item 1 was created using blood collected from a male donor. Item 2 was created using blood collected from a female donor. The Item 3 mixture was created by combining two parts of blood from the Item 2 female donor and three parts of blood from a 3rd party female donor. The Item 4 mixture was created by combining five parts of blood from the Item 2 female donor, two parts of blood from a 3rd party male donor, and two parts of blood from a 4th party female donor.

SAMPLE SET ASSEMBLY: Once sample preparation and verification was completed, the digital upload was checked to ensure all items were accessible.

VERIFICATION: Laboratories that conducted predistribution testing of the electropherograms reported consistent results for all loci. All associations were consistent amongst the predistribution laboratories.

Consensus data on the following pages was determined by ensuring at least 10 participants returned results for the locus. Each allele listed was determined by ensuring that at least 75% of participants that returned data for that specific locus and item had reported the same allele.

Test No. 19-589: DNA Interpretation

Amelogenin and STR Results

Results compiled by predistribution laboratories and a consensus of participants.

Item	D1S1656	D2S1338	D2S441	D3S1358	D5S818	D7S820
	D8S1179	D10S1248	D12S391	D13S317	D16S539	D18S51
	D19S433	D21S11	D22S1045	Amelogenin	CSF1PO	FGA
	Penta D	Penta E	SE33	TH01	TPOX	vWA
	DYS391	DYS570	DYS576	Y Indel		
1	11,16	19,22	10,11	15,16	11,12	9,10
	11,15	13,14	18,19	12,12	9,12	12,13
	13,13	30,30	15,18	X,Y	10,10	25,28
	9,12	10,11	17,27.2	8,9.3	6,8	14,16
	9	17	17	2		
2	16,16.3	19,24	11,11.3	15,16	11,13	8,13
	13,15	13,15	20,22	10,12	11,12	12,14
	14,14.2	28,30	15,16	X,X	10,11	22,24
	8,12	11,12	21,28.2	6,9	8,9	15,19
	NM	NM	NM	NM		
3	12,13,16,16.3†	16,18,19,24	11,11.3	15,16,17,18	10,11,13	8,10,11,13
	12,13,14,15	13,15,16	19,20,22	9,10,12	9,11,12	12,14,15,19
	14,14.2,15	28,30,32.2	11,15,16	X,X	10,11,13	22,24
	8,12	10,11,12	15,21,27.2,28.2	6,9,9.3	8,9	15,18,19
	NM	NM	NM	NM		
3major	*	*	11	*	13	*
	*	13	20	10	12	*
	14	28	15	X,X	11	22,24
	*	*	*	6	8	15
	NM	NM	NM	NM		
3minor	*	*	11	*	13	*
	*	*	*	*	*	*
	*	*	*	X,X	11	22
	*	*	*	*	8	*
	NM	NM	NM	NM		
4	15,16,16.3	19,20,21,23,24	11,11.3,13	15,16	11,13	8,9,11,13
	10,11,12,13,15	13,14,15	15,20,21,22,23	9,10,12	9,11,12,13	12,13,14,15,16
	13,14,14.2,15	28,29,30,32.2	15,16	X,Y	9,10,11	18,22,23,24,26,30
	6,8,11,12,13	7,11,12,13	16,18,19,21,25.2,28.2	6,8,9,9.3	8,9,10,11	15,16,18,19
	11	20	17	2		

YSTR Results

Results compiled from predistribution laboratories and a consensus of participants.

Item	DYS19	DYS385	DYS389-I	DYS389-II	DYS390	DYS391	DYS392	DYS393
	DYS437	DYS438	DYS439	DYS448	DYS456	DYS458	DYS481	DYS533
	DYS549	DYS570	DYS576	DYS635	DYS643	YGATAH4		
1	16	12,12	14	29	25	9	11	14
	15	10	11	21	13	17	21	12
	9	17	17	21	12	11		
4	17	11,14	14	31	25	11	11	13
	14	11	10	19	16	15	23	12
	12	20	17	23	11	11		

NM - Non-Male profile, YSTR results not expected.
* Results were not received from a minimum of 10 participants for the loci indicated.
† Additional alleles may be present depending on laboratory thresholds.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.